Nifuroksazyd Hasco (Nifuroxazide)

Nifuroxazide, the active ingredient in Nifuroksazyd Hasco, is a nitrofuran antibacterial presented as an oral tablet for oral use. It is employed to treat acute infectious diarrhea and travelers' diarrhea by targeting bacterial pathogens in the intestinal lumen. The drug remains largely confined to the gastrointestinal tract, providing a localized antibacterial effect without significant systemic absorption.

GNH USA supplies Nifuroksazyd Hasco as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance.

Nifuroxazide is indicated for bacterial gastrointestinal infections and works by reducing pathogen load in the intestinal tract.

- Acute infectious diarrhea: reduces stool frequency and volume by inhibiting growth of causative bacteria. - Travelers' diarrhea: provides symptomatic relief and shortens illness duration in travelers exposed to contaminated food or water. - Bacterial dysentery: helps control bloody diarrhea caused by susceptible enteric bacteria.

Nifuroxazide may cause adverse reactions, most of which are mild and self‑limiting.

Common Side Effects: - Nausea: mild stomach upset occurring in some patients. - Abdominal cramps: intermittent discomfort during treatment. - Flatulence: increased intestinal gas. - Diarrhea persistence: occasional continuation of symptoms. - Skin rash: mild erythematous eruption.

Serious or Rare Side Effects: - Severe allergic reaction: anaphylaxis or angioedema requiring immediate medical attention. - Hepatotoxicity: signs of liver injury such as jaundice or elevated enzymes. - Clostridioides difficile infection: rare overgrowth leading to colitis. - Hematologic abnormalities: unexplained bruising or low blood counts.

Before prescribing Nifuroxazide, clinicians should consider several safety aspects to minimize risk.

- Pregnancy: use only if potential benefit outweighs risk, as safety data are limited. - Breastfeeding: caution advised; drug may be excreted in milk. - Renal impairment: monitor patients with severe kidney dysfunction. - Concomitant antibiotics: avoid simultaneous use with broad‑spectrum agents that may alter gut flora. - Allergies: discontinue if hypersensitivity reactions develop. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Nifuroxazide can interact with other medicines, affecting its efficacy or safety profile.

Major Interactions (Avoid): - Antimicrobial agents with overlapping spectrum: may reduce effectiveness of Nifuroxazide. - Probiotics containing live bacteria: could counteract antibacterial action.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may alter gastrointestinal pH and affect drug dissolution. - Oral contraceptives: monitor for reduced contraceptive reliability. - Warfarin: observe INR values as gut flora changes may influence vitamin K synthesis. - Diuretics: watch for electrolyte disturbances if diarrhea persists.